|
1
|
Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, et al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 59:2083–2091. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Toshikuni N: Therapy with direct-acting antiviral agents for hepatitis C-related liver cirrhosis. Gut Liver. 11:335–348. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, et al: Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 65:719–726. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: simplestanislas.pol@aphp.fr. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 65:734–740. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, et al: Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 65:727–733. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y and El-Serag HB: Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 153:996–1005.e1. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Otani S, Kawai-Kitahata F, et al: Ochanomizu Liver Conference Study Group: Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 67:933–939. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mashiba T, Joko K, Kurosaki M, Ochi H, Osaki Y, Kojima Y, Nakata R, Goto T, Takehiro A, Kimura H, et al: Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS One. 13(e0194704)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Nagaoki Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, et al: Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res. 50:1222–1233. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Asahina Y, Izumi N, Hiromitsu K, Kurosaki M, Koike K, Suzuki F, Takikawa H, Tanaka A, Tanaka E, Tanaka Y, et al: JSH Guidelines for the management of hepatitis C virus infection: A 2016 update for genotype 1 and 2. Hepatol Res. 46:129–165. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM and Rodés J: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 36:986–992. 2002.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, et al: The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy. J Med Virol. 91:650–658. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Llovet JM and Villanueva A: Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol. 13:561–562. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nishibatake Kinoshita M, Minami T, Tateishi R, Wake T, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, et al: Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. J Hepatol. 70:78–86. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, et al: Kyushu University Liver Disease Study (KULDS) Group: Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther. 47:104–113. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, et al: HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology. 156:2313–2329.e7. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rout G, Nayak B, Patel AH, Gunjan D, Singh V and Kedia S: Shalimar. Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography. J Clin Exp Hepatol. 9:207–214. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ogasawara N, Kobayashi M, Akuta N, Kominami Y, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Suzuki F, Saitoh S, et al: Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. J Med Virol. 90:313–319. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, et al: APRICOT Clinical Investigators: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 43:1317–1325. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS and Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 38:518–526. 2003.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jafri H, Alsheikh-Ali AA and Karas RH: Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol. 55:2846–2854. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Carr BI, Giannelli G, Guerra V, Giannini EG, Farinati F, Rapaccini GL, Marco MD, Zoli M, Caturelli E, Masotto A, et al: Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. Int J Biol Markers. 33:423–431. 2018.PubMed/NCBI View Article : Google Scholar
|
